IceCure Medical’s ProSense® Shows Promising Results

Icecure Medical (ICCM) has released an update.

IceCure Medical’s ProSense® system has been highlighted for its 100% success rate in destroying breast tumors ≤ 25mm in a study of patients who opted for cryoablation over surgery. The study, published in the British Journal of Radiology, demonstrates cryoablation as a safe, effective outpatient alternative to surgery, particularly favored by the elderly. These results may indicate a growing demand for IceCure’s non-surgical treatment option in light of an aging population at increased risk for breast cancer.

For further insights into ICCM stock, check out TipRanks’ Stock Analysis page.